Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31116092 | 0.79 | ALDH1A1 (0.33) | ALDH1A1GRM1 | |
| SCHEMBL10210793 | 0.77 | ALDH1A1 (0.35) | ALDH1A1GRM1 | |
| SCHEMBL19614682 | 0.77 | GRM1 (0.34) | ALDH1A1GRM1 | |
| SCHEMBL16700084 | 0.77 | ALDH1A1 (0.32) | ALDH1A1GRM1 | |
| SCHEMBL478303 | 0.74 | GRM1 (0.40) | GRM1 | |
| SCHEMBL23327151 | 0.74 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL10160156 | 0.72 | ALDH1A1 (0.33) | ALDH1A1GRM1 | |
| SCHEMBL4036460 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL20294175 | 0.70 | GRM1 (0.34) | GRM1 | |
| SCHEMBL25135435 | 0.70 | CYP2D6 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219492-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-08-02 | — | — | EP | claimed |
| EP-3790877-B1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORP (US) | 2023-03-01 | — | — | EP | claimed |
| US-20220348594-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-11-03 | — | — | US | claimed |
| CN-114249726-A | Biphenyl compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2022-03-29 | — | — | CN | claimed |
| US-20210115068-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-22 | — | — | US | claimed |
| EP-3790877-A1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | claimed |
| US-10906920-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2021-02-02 | — | — | US | claimed |
| US-20200277309-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-09-03 | — | — | US | claimed |
| US-20190345170-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-11-14 | — | — | US | claimed |
| WO-2019217821-A1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2019-11-14 | — | — | WO | claimed |
| EP-4219492-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3790877-B1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORP (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220348594-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-11-03 | — | — | US | disclosed |
| US-11414433-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| CN-114249726-A | Biphenyl compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-10906920-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200277309-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-09-03 | — | — | US | disclosed |
| US-10618916-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190345170-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-11-14 | — | — | US | disclosed |
| WO-2019217821-A1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906920-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | ALDH1A1 223/4885GRM1 2248/4885 |
| US-20210115068-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | ALDH1A1 223/4885GRM1 2248/4885 |
| US-10618916-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | ALDH1A1 223/4885GRM1 2248/4885 |
| US-11414433-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | ALDH1A1 223/4885GRM1 2248/4885 |
| US-20200277309-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | ALDH1A1 223/4885GRM1 2248/4885 |
| US-20220348594-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | ALDH1A1 223/4885GRM1 2248/4885 |
| US-20190345170-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | ALDH1A1 223/4885GRM1 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.